FCM
ABBV icon

Fourpath Capital Management’s AbbVie ABBV Stock Holding History

Fourpath Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Sell
5,401
-50
-0.9% -$11.1K 0.17% 95
2025
Q4 		$1.25M Sell
5,451
-2,706
-33% -$616K 0.17% 90
2025
Q3 		$1.89M Sell
8,157
-16
-0.2% -$3.26K 0.27% 72
2025
Q2 		$1.52M Buy
8,173
+454
+6% +$84.4K 0.24% 76
2025
Q1 		$1.62M Buy
7,719
+293
+4% +$57K 0.28% 71
2024
Q4 		$1.32M Buy
7,426
+876
+13% +$161K 0.24% 81
2024
Q3 		$1.29M Buy
6,550
+406
+7% +$75.8K 0.24% 80
2024
Q2 		$1.05M Sell
6,144
-314
-5% -$52K 0.78% 23
2024
Q1 		$1.18M Sell
6,458
-2,229
-26% -$384K 0.82% 23
2023
Q4 		$1.35M Buy
8,687
+582
+7% +$84.8K 0.91% 19
2023
Q3 		$1.21M Sell
8,105
-215
-3% -$31.6K 0.91% 25
2023
Q2 		$1.12M Sell
8,320
-1,231
-13% -$181K 1.35% 19
2023
Q1 		$1.52M Sell
9,551
-456
-5% -$69.7K 1.07% 15
2022
Q4 		$1.62M Sell
10,007
-418
-4% -$64.1K 1.18% 15
2022
Q3 		$1.4M Sell
10,425
-718
-6% -$103K 0.96% 22
2022
Q2 		$1.71M Sell
11,143
-3,872
-26% -$592K 1.06% 17
2022
Q1 		$2.43M Sell
15,015
-1,595
-10% -$232K 0.97% 22
2021
Q4 		$2.25M Buy
+16,610
New +$1.96M 0.86% 20

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fourpath Capital Management's ABBV Position: Q1 2026 in Review

Fourpath Capital Management reduced its AbbVie (ABBV) stake by 0.92% in Q1 2026, selling an estimated $11.1K and leaving 5,401 shares worth $1.17M. The position accounts for 0.17% of the portfolio, ranked #95.

Fourpath Capital Management first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.43M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Fourpath Capital Management held 5,401 shares of AbbVie worth $1.17M as of Q1 2026.
  • Fourpath Capital Management sold 50 AbbVie shares in Q1 2026, an estimated $11.1K.
  • AbbVie made up 0.17% of Fourpath Capital Management's portfolio in Q1 2026, its #95 holding.
  • Fourpath Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • Fourpath Capital Management's AbbVie position peaked at $2.43M in Q1 2022.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.